報價延遲最少15分鐘:2026/06/02 18:23 EDT
盤後時段
|
||||
|
15.8 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.35/-2.37
|
|
企業價值
1.92B
|
| 資產負債 |
|
每股賬面淨值
4.56
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
70.85M
|
|
每股收益
0.01
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibodytargeting IGF-1R intravenously administered for the treatment of TED. |
